Drug Doses & Preparation | Professional clinical monograph | Updated 22 October 2026
Dexamethasone sodium phosphate is a potent long-acting injectable glucocorticoid. Its dose, route and duration depend on the indication. Always verify the vial’s actual strength expression, approved routes, preservatives and institutional protocol.
Dexamethasone quick note sheet
- Class: long-acting glucocorticoid with minimal mineralocorticoid activity.
- Examples of injection strengths: 4 mg/mL and 10 mg/mL; check whether the stated mg refer to dexamethasone phosphate equivalent.
- Routes: IV and IM; local injection only when specifically permitted by the product label.
- Reconstitution: generally unnecessary for ready-to-use solution.
- IV: direct administration or dilution with compatible sodium chloride/dextrose for drip may be permitted by the specific label; no universal push rate or dilution volume.
- Core formula: mL = prescribed mg ÷ labelled mg/mL, provided the dose-equivalent convention matches.
- Major monitoring: blood glucose, infection, BP, mental status and treatment duration.
- Critical warning: steroids do not replace IM adrenaline in anaphylaxis.
Pharmacology and mechanism
Dexamethasone binds intracellular glucocorticoid receptors and changes gene transcription, reducing inflammatory mediators and vascular permeability. It can also suppress immune responses, increase blood glucose and cause adrenal suppression with sufficient exposure. It is not interchangeable with hydrocortisone for mineralocorticoid replacement.
Available injection formulations
| Example strength | Product-label routes | Important qualification |
|---|---|---|
| 4 mg/mL | IV, IM; some labels allow intra-articular, intralesional or soft-tissue injection | Check exact product and preservative |
| 10 mg/mL | IV and IM on referenced label | Do not assume suitability for local injection |
One label expresses 4.4 mg dexamethasone sodium phosphate as equivalent to 4 mg dexamethasone phosphate per mL. Base and phosphate-equivalent amounts are not interchangeable without verification.
Clinical indications
Selected tumour-associated vasogenic cerebral oedema, severe steroid-responsive inflammatory or allergic disease, specific respiratory disorders, adjunctive therapy for certain bacterial meningitis protocols, and oncology-related indications. It is not routinely indicated for traumatic brain injury, uncomplicated viral fever or undifferentiated cough.
Adult doses by indication
Reference regimens are indication-specific, not interchangeable prescriptions.
| Indication | Reference regimen | Clinical caveat |
|---|---|---|
| General steroid-responsive conditions | Manufacturer-labelled initial range approximately 0.5–9 mg/day IV/IM | Individualise to diagnosis and response |
| Selected cerebral oedema | 10 mg IV initially, then 4 mg IM every 6 hours | Product-label example; specialist reassessment and taper |
| Community-acquired bacterial meningitis | 10 mg IV every 6 hours for 4 days in selected adults | Before or with first antibiotic; never delay antibiotics |
| Selected acute allergic disorders | Older product-label example: 4–8 mg IM initially | Not first-line for anaphylaxis |
Cerebral oedema
The cited injection label describes 10 mg IV followed by 4 mg IM every six hours, then reducing after improvement and tapering under supervision. This does not apply to every cause of raised intracranial pressure.
Bacterial meningitis
Adjunctive dexamethasone must be timed before or with the first antibiotic dose when indicated; management and continuation depend on the pathogen, local epidemiology and current guidelines. Antibiotics and emergency care take priority.
Paediatric dosing: indication-specific
There is no universal paediatric IV/IM dose. The Royal Children’s Hospital croup guideline gives 0.15 mg/kg orally for moderate croup and 0.6 mg/kg PO/IM/IV (maximum 12 mg) for severe croup; life-threatening croup requires emergency airway management, with nebulised adrenaline as indicated. These croup doses must not be transferred to meningitis or cerebral oedema.
Paediatric calculation example
For a 12 kg child with severe croup, 0.6 mg/kg gives 7.2 mg. At 4 mg/mL, this is 1.8 mL; at 10 mg/mL, 0.72 mL. This is a worked example, not a stand-alone prescription. Confirm strength convention, product suitability, route and maximum dose.
Neonatal precautions
Preservative-containing solutions may be inappropriate in neonates, particularly premature infants. The cited label calls for preservative-free solutions for neonatal IV use or further dilution. Specialist neonatal protocols are essential.
IV preparation and administration note sheet
- Confirm identity, indication, prescribed mg dose, route, interval and duration.
- Read vial strength, salt-equivalence expression, expiry, preservative status and permitted route.
- Inspect solution and container for particles, discoloration or damage.
- Calculate withdrawal volume using prescribed mg divided by verified mg/mL.
- For direct IV or infusion, follow the specific manufacturer’s instructions and institutional injectable-medicines guide; do not invent a universal IV push rate.
- If preparing an infusion, verify sodium chloride or dextrose compatibility for the specific product, prepare aseptically and label final dose, concentration and beyond-use time.
- Monitor the IV site, clinical response and adverse effects; document administration.
Volume calculation table
| Dose | 4 mg/mL | 10 mg/mL |
|---|---|---|
| 2 mg | 0.5 mL | 0.2 mL |
| 4 mg | 1 mL | 0.4 mL |
| 6 mg | 1.5 mL | 0.6 mL |
| 8 mg | 2 mL | 0.8 mL |
| 10 mg | 2.5 mL | 1 mL |
| 12 mg | 3 mL | 1.2 mL |
These are arithmetic conversions only. The cited label allows direct administration or IV drip with compatible sodium chloride/dextrose solutions, but exact infusion concentration, administration rate and beyond-use time must be product- and institution-specific.
IM administration
Use the approved product, an appropriate muscle and aseptic technique. IM absorption is slower than IV administration. Route selection depends on urgency, indication and formulation.
Renal and hepatic considerations
There is no standard dexamethasone injection dose reduction based solely on eGFR, but renal disease increases concern about blood pressure, glucose and infection. No universally applicable hepatic-adjustment table exists; individualise in significant liver disease and check drug interactions. Do not assume a dialysis supplement is required.
Pregnancy and lactation
Systemic corticosteroids may be appropriate in pregnancy for a clear indication; choice of steroid and dosing depends on the maternal or fetal objective. Antenatal fetal maturation uses separate obstetric protocols. Breastfeeding assessment depends on dose, duration and infant factors; do not automatically advise interruption after every dose.
Contraindications and precautions
- Check product-specific hypersensitivity and systemic fungal infection contraindications.
- Review active or latent infection, diabetes, hypertension, gastrointestinal bleeding risk, psychiatric disease, glaucoma and concomitant immunosuppressants.
- Corticosteroids can mask infection and worsen hyperglycaemia.
Adverse effects and monitoring
| Area | Concern |
|---|---|
| Metabolic | Hyperglycaemia |
| Cardiovascular | BP and fluid-related effects |
| Psychiatric | Insomnia, agitation, mood changes |
| Infection | Increased susceptibility and masked signs |
| Gastrointestinal | Ulceration or bleeding risk |
| Endocrine | Adrenal suppression after sufficient exposure |
| Long-term | Myopathy, osteoporosis, cataract, glaucoma |
Monitor clinical response, glucose, BP, infection, mental status and cumulative exposure. Prolonged systemic therapy may require a supervised taper; brief courses do not always require tapering.
High-risk medication errors
- Confusing 4 mg/mL with 10 mg/mL.
- Confusing dexamethasone base and phosphate-equivalent strength.
- Copying a cerebral-oedema regimen into an unrelated indication.
- Assuming every brand has the same IV push rate or dilution.
- Using dexamethasone instead of adrenaline in anaphylaxis.
- Ignoring hyperglycaemia, infection and preservative risk in neonates.
- Abruptly stopping prolonged steroid therapy without assessing adrenal suppression.
Clinical FAQs
Does it require reconstitution?
Not when supplied as a ready-to-use solution; verify the product.
Can it be given IV without dilution?
Some labels allow direct IV use, but the exact administration method and rate must be checked for the product.
Can it be mixed with normal saline?
Selected labels permit sodium chloride injection for IV drip; this does not prove universal compatibility with all concentrations, containers or co-administered medicines.
Can it raise blood sugar?
Yes; clinically important steroid-induced hyperglycaemia can occur.
Is it an antibiotic?
No. It is a glucocorticoid and does not directly treat bacterial infection.
Is tapering always necessary?
No. Assess dose, duration and clinical circumstances.
Clinical takeaway
Choose the indication first, verify the actual formulation second, and calculate the dose and administration method only after both are confirmed. Monitor response and complications throughout treatment.
Primary references
- DailyMed: Dexamethasone Sodium Phosphate Injection prescribing information
- DailyMed: Injectable dexamethasone product information
- Royal Children’s Hospital: Croup guideline
- Neurocritical Care Society: Acute treatment of cerebral edema
For healthcare professional education. Verify Indian product labels and current local protocols before prescribing or administering.